

Review Article

Regulatory T Cells and Parasites

TP. Velavan¹ and Olusola Ojurongbe^{1,2}

¹*Institute for Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany*

²*Department of Medical Microbiology and Parasitology, Ladoko Akintola University, PMB 4400, Osogbo, Nigeria*

Correspondence should be addressed to TP. Velavan, velavan@medizin.uni-tuebingen.de

Received 30 June 2011; Revised 19 September 2011; Accepted 4 October 2011

Academic Editor: Luis I. Terrazas

Copyright © 2011 TP. Velavan and O. Ojurongbe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human host encounters a wide array of parasites; however, the crucial aspect is the failure of the host immune system to clear these parasites despite antigen recognition. In the recent past, a new immunological concept has emerged, which provides a framework to better understand several aspects of host susceptibility to parasitic infection. It is widely believed that parasites are able to modulate the magnitude of effector responses by inducing regulatory T cell (Tregs) population and several studies have investigated whether this cell population plays a role in balancing protective immunity and pathogenesis during parasite infection. This review discusses the several mechanism of Treg-mediated immunosuppression in the human host and focuses on the functional role of Tregs and regulatory gene polymorphisms in infectious diseases.

1. Immunomodulation by Parasites

In this paper, we specify parasites as eukaryotic pathogens that largely include protozoa and helminths and survive off their host partly or completely for their life cycle. They employ various strategies to evade against an effective host innate immune system. Innate immunity rarely eliminates parasites but can successfully inhibit growth while they recruit antigen-specific T and B cells to differentiate into effector cells that thwart the infection [1]. For an effective parasite survival, evasion of adaptive immunity remains the key [2]. In this scenario, parasites strike a balance with the host immune system to increase their survival rate. This balance is accomplished by complex alteration of the innate and acquired immune response of the host where regulatory T (Tregs) cells play an important role [3].

2. Regulatory T Cells

Understanding the complex cellular and molecular mechanism that regulates the host immune response to parasitic infections still remains a key issue in immunology. The crippling effect of host immunity on onset of an infection is due to the fact that parasites induce Tregs that in turn suppress antiparasite effector cells [4]. The Tregs are a subset of T cells

that function to control immune responses. The primary role of Tregs is active suppression of several pathological and physiological immune responses in the host, thereby contributing to the maintenance of immune homeostasis [5–7]. Although Tregs are defined as T cells with suppressive activity on immune responses, it had been documented that regulatory T cell populations remain diverse [8]; a few of them are induced in response to infectious challenge and the others are considered as natural regulators [9]. Parasites can ably manipulate natural Tregs by amending the T cell immune response at the infection site to an extent that could lessen the infection burden, thereby prevailing in the host for a longer time frame [10]. The well-characterized Tregs are CD4⁺CD25⁺ population and represent about 10% of peripheral CD4⁺ T cells both in mice and humans [11]. Tregs are considered as negative regulators of T cell immune response and these natural Tregs originate during thymic development and appear first in the fetal circulation [12]. The suppressor activity is enriched in naturally occurring Tregs such as CD4⁺CD25⁺ that plays a vital role in the initiation and orchestration of immune responses [13, 14]. The CD4⁺CD25⁺ population reveals a high expression of Foxp3 transcription factor which is vital for differentiation and function of naturally occurring Treg cells [15] and for programming the suppressor T cell function [16, 17]. Foxp3⁺

Tregs play an essential role in controlling the voracity of the response as they generally strike a balance that limits potentially harmful immune-mediated pathology to the host while still allowing sufficient immune pressure against the pathogen [18].

3. Mechanism of Suppression

T-cell receptors remain the key to trigger suppressive function in both naturally occurring and induced Tregs [19]. The regulation of T cells is either by contact-dependent regulation or by soluble factors such as immunosuppressive cytokines. To date, no precise mechanism has been clearly postulated to explain the suppressor function exhibited by Tregs.

3.1. Contact-Dependent Mechanism. Many different hypotheses have demonstrated how Tregs are regulated based on the contact-dependent suppressive mechanism. However, two specific mechanisms are reviewed here. One mechanism is the interaction of T effector ligand CD80 and CD86 with cytotoxic-T-lymphocyte-associated protein (CTLA-4). This interaction triggers the transmission of immunosuppressive signals on T effector cells thus inhibiting effector T-cell function [20] (Figure 1(a)). CTLA-4 is expressed at high levels on CD4⁺CD25⁺ Tregs, and there is substantial evidence that CTLA-4 expressed by natural Tregs has a key role in Treg-mediated suppression both *in vivo* and *in vitro* [6, 21, 22]. In another model, the costimulatory molecules CD80 and CD86 expressed in antigen-presenting cells (APCs) interact with CTLA-4 leading to consequential signalling and activation of IDO (indoleamine 2,3 dioxygenase) in dendritic cells (DCs), an enzyme responsible for immune tolerance on effector T cells [23] (Figure 1(b)). IDO catalyzes the conversion of tryptophan to kynurenine that provides immunosuppressive effects in the local environment of DCs by cytotoxicity or by *de novo* generation of Tregs [8]. Studies have reported decreased activation of T cells and T cell deletion in association with reduced tryptophan concentration in cultures [23, 24]. Studies have also demonstrated that human adaptive Tregs preferentially expressed granzyme B and are capable of killing allogenic tumour cells in a perforin-dependent manner [25]. In line with these studies, it is demonstrated that both subtypes CD4⁺CD25⁺ Tregs exhibit perforin-dependent cytotoxicity against a variety of autologous target cells including CD4⁺, CD8⁺, CD14⁺ monocytes and dendritic cells [26].

3.2. Immunosuppressive Cytokine Mediated. In contrast to contact dependent suppressive mechanism, reports indicate that cytokines such as IL-10 and transforming growth factor (TGF- β) are needed for *in vitro* mediating suppression [27, 28]. Several *in vivo* studies have indicated the role of immune suppressive cytokines in suppression. In this model, Treg-dependent inhibition of tumor-specific CD8 T cell-mediated cytotoxicity requires expression of the TGF- β receptor by CD8 cells thereby demonstrating a specific role of TGF- β signaling in the inhibition of cytotoxicity

independent of cellular proliferation [29] (Figure 1(c)). The IL-10 cytokine hampers the antigen presenting ability by downregulating the MHC class II and costimulatory molecules on DCs thereby preventing the maturation and activation of dendritic cells both in humans and in mice [30]. TGF- β also downregulates the MHC class II expression and costimulatory molecules on DCs [31].

In addition, in mouse models, a recent study had demonstrated that helminth parasites have evolved a novel mechanism to directly expand Foxp3⁺ Tregs which may be a key part of the parasite's strategy to survive in the host for a longer time [32]. On infection with intestinal helminth *H. polygyrus*, an expansion of the Foxp3-expressing CD4⁺ T cells was observed. The *H. polygyrus* excretory-secretory antigen (HES) induced Tregs and was demonstrated to suppress *in vitro* effector cell proliferation. The hypothesis proposed that HES ligated the transforming growth factor TGF- β receptor and promoted Smad2/3 phosphorylation. The Foxp3 induction by HES was lost in dominant-negative TGF- β RII cells and was eliminated by the TGF- β signaling inhibitor [32].

4. Tregs and Tropical Diseases

Tregs can reduce injurious host inflammatory and immune responses through mechanisms of cell-to-cell contact, inhibitory cytokines, and cytokine deprivation. This prevents an overexuberant immune response with bystander tissue damage during the host response to infections [33]. However, Tregs may also blunt Th2 responses such as IL-5-dependent eosinophil activation required to kill parasites. The interplay and balance among host Th1, Th2 and Tregs responses is crucial in the defense against a parasitic infection [34]. Some of the earliest studies emphasized that natural Tregs help control the extent of immune-mediated pathology. During malarial infection increased numbers of CD4⁺CD25⁺Foxp3⁺ T cells have been found in both human and murine malaria infection [35, 36]. Evidences of the role of Tregs as suppressors of T-cell responses in malaria was initially demonstrated in murine models, where Tregs are known to be associated with increased or delayed parasite growth [37, 38]. Higher Tregs numbers are associated with increased parasite load and development of human infection caused by *P. falciparum* [39, 40]. Given these associations between severe disease and exacerbated immune pathology, a number of studies have explored the role of CD4⁺CD25^{hi} Foxp3⁺CD127^{-/lo} Tregs in determining the outcome of malaria infection. In a study conducted among Gambian children with severe, uncomplicated clinical malaria and with healthy (controls), Tregs were unable to control the inflammation during acute and severe *P. falciparum* infections, suggesting that this component may be rapidly overwhelmed by virulent infections [41]. Tregs may be beneficial to the host in the later part of the infection—when parasitemia is being cleared—by downregulating the inflammatory response and thereby preventing immune-mediated pathology [41]. On the other hand, if Tregs mediate their suppressive effects too early, this could hamper the responses required for initial control of parasitemia,




FIGURE 1: Mechanism(s) of suppression: illustrates various molecular and cellular mechanisms to explain how Tregs can suppress host immune responses. (a) In contact dependent mechanism the costimulatory molecules, namely, CD80/86, interact with CTLA-4 to trigger immunosuppressive signals on T effector cells leading to subtle effector cell function. (b) In contact dependent mechanism, CD80/86 expressed in APC interact with CTLA-4 leading to consequential signalling and activation of IDO leading to immunosuppressive effects. (c) The crosstalk of TGFβ expressed in APC to TGFβ II receptor leads to immunosuppressive cytokine-mediated suppressor function.

permitting unbridled parasite growth, which may also lead to severe disease. It was also demonstrated that patients with acute *P. vivax* infection presented a significant augmentation of circulating Tregs producing anti-inflammatory (IL-10 and TGF-β) as well as pro-inflammatory (IFN-γ, IL-17) cytokines, which were further positively correlated with circulating parasites [42]. Malaria-specific induction of Tregs has been observed in a variety of experimental malaria infections in mice [36, 43], but their role in preventing severe malarial pathology is still unclear.

Tregs are widely believed to be involved in silencing the immune response during chronic stages of any filarial

infection. Although patients with chronic Onchocerciasis (river blindness) possess higher worm burden, they reveal little/no signs of dermatitis. Studies have argued that Tr1 (a subset of CD4⁺ T cells) induce a substantial increase in IL-10, IL-5, and IFN-γ levels conferring an immunosuppressive effect [44] in chronic onchocerciasis individuals, whereas in animal models studies had demonstrated that a subtle immune response is mediated by female worms [45, 46] and is dependent on TGF-β and IL-10, two cytokines closely implicated in the activity and induction of Tregs [47–49]. In *Litomosoides sigmodontis* model, the infective L3 stage induces the proliferation of CD4⁺Foxp3⁺ Tregs,

which translates to an increased percentage of CD4⁺ T cell population at the site of infection expressing Foxp3⁺ cells within 7 days after infection [49]. The CD4⁺ regulatory T cell population has also been found significantly higher in several other filarial infections, including *Brugia malayi* [50], the gastrointestinal nematode *Heligmosomoides polygyrus* [51, 52], and the gut/muscle-dwelling nematode *Trichinella spiralis* [53].

Chagas, a tropical disease caused by *Trypanosoma cruzi* is known to cause cardiomyopathy, an inflammatory response in the heart [54]. The occurrence of larger proportion of Foxp3⁺ population has been demonstrated to control the inflammatory responses in the heart during chagas disease [55]. Therefore, Foxp3⁺ cells may be involved in a possible mechanism to prevent exacerbation of the inflammatory responses [54, 55]. A similar pattern of Tregs role was established with African trypanosomiasis in a mouse models where naturally occurring Foxp3⁺ Tregs induce IL-10 production with subtle IFN-gamma response by CD4⁺ and CD8⁺ effector T cells. In addition, Tregs also downregulate classical activation of macrophages resulting in decreased activity of TNF-alpha [56]. The Treg activity is believed to decrease the tissue damage in the host cells suggesting a cardinal role for naturally occurring Tregs in the development of a tolerant phenotype during African trypanosomiasis [57].

The immune response against *T. gondii*, an intracellular parasite and the etiological agent of toxoplasmosis, has been largely characterized and demonstrated that cellular immunity plays a vital role in controlling infections [58]. Of which, Tregs were demonstrated to modulate the protective immune response against *T. gondii*, thereby driving a powerful Th1 immune response [59, 60]. Also, it is believed that the absence of Tregs in toxoplasmosis may induce an uncontrolled inflammatory response [60].

Foxp3-expressing Tregs have been implicated in parasite-driven inhibition of host immunity during chronic infection [32]. One of the major effects of chronic helminth infections is induction of T-cell hypo responsiveness [61]. The mechanisms involved have been thought to be multiple and the involvement of natural and inducible Tregs in down regulating effector T cell responses upon chronic infection has been proposed [62]. The cytokines IL-10 and TGF-β have been associated with down regulation, indicating that regulatory populations are activated during infection. The importance of IL-10 as a crucial mediator of regulation in parasite infections has been well recognized both in humans and murine [63–65]. In human filariasis, heavily infected individuals have high IL-10 levels and IL-10 messenger RNA production which was inversely correlated with T cell proliferation [34, 66]. Similarly infection in experimental *Schistosoma mansoni* was shown to be associated with immunoregulatory mechanisms, including Treg that may help control morbidity and dampen resistance to reinfection. Treg responses control both Th1 and Th2 responses in an IL-10 independent manner [67, 68] and are associated with regulation of granuloma formation in chronic infections [69]. In a study conducted among patients infected with *S. mansoni* in Kenya, it was revealed that few patients had higher proportions

of CD3⁺/CD4⁺/CD25^{high} Tregs that subsequently decreased after treatment with praziquantel. The study concluded that not all *Schistosoma mansoni*-infected individuals develop high percentages of circulating Tregs. The effective treatment decreases the proportion of Tregs and their phenotypes, possibly because of the removal of constant exposure to antigens from intravascular, egg-producing adult worms [70]. In a NOD mice model, treatment with *S. mansoni* egg antigen (SEA) was shown to upregulate TGF-β on T cells and Th2 cells resulting in the expansion of Foxp3⁺ that remain crucial in determining the SEA-mediated diabetes outcome [71]. Also, hsp60 peptide (SJMHE1) of *S. japonicum* induces CD4⁺CD25⁺Foxp3⁺ Tregs both *in vivo* and *in vitro* resulting in subsequent release of IL-10 and TGF-β [72].

Nematode infections have been shown to induce regulatory cell expansion in both mice and humans [73]. In a study conducted in Lima, Peru, among human T lymphocyte virus (HTLV-1) patients with or without *Strongyloides* infection, increased proportions of CD4⁺CD25⁺Foxp3⁺ Tregs were observed in patients with *S. stercoralis* and HTLV-1 coinfection in comparison to normal controls [33]. Furthermore, those with increased proportions of CD25⁺FoxP3⁺ cells had decreased antigen driven production of IL-5 and lower eosinophil counts. This reduced response is inversely correlated with the proportion of CD4 cells, which are CD4⁺CD25⁺FoxP3⁺, suggesting a role for these cells in blunting antigen-driven protective responses.

Visceral Leishmaniasis (VL) represents a parasitic disease that has been shown not to induce expansion of natural Tregs. In a study conducted among patients presenting with symptoms of Kala-azar, frequencies of Foxp3⁺ cells in patient with VL before and after treatment did not increase, neither were they elevated when compared to endemic controls. It was therefore concluded that active VL is not associated with increased frequencies of peripheral Foxp3 Treg or accumulation at the site of infection [74]. While active VL does not induce expansion of Treg, it has been shown in animal models that Treg is directly responsible for its reactivation [75]. During the primary infection, *L. major* can disseminate to other tissues within the body which may persist after parasite reduction and healing [76, 77]. These persistent parasites are associated with the establishment of strong immunity against reinfection, a state that is referred to as concomitant immunity [75, 78, 79]. Tregs have been found abundantly at these reinfection sites while it reduces at the site of initial infection confirming its importance in reactivation of VL infection. Significant increase in IL-10 production by dermal and LN CD4⁺ T cells has been shown during the reactivation process confirming a role of IL-10 mediated *Leishmaniasis* both in susceptible and resistant individuals [80, 81]. In macaque (*Macaca mulatta*) model, *L. braziliensis* strain that produces self-healing dermal lesions was used to characterize the systemic and local cell-mediated immune responses that led to controlled growth of granulomas in the infected host. Resolution of infection was observed to be dependent on concomitant recruitment of interleukin- (IL-)10-producing CD4⁺CD25⁺ regulatory T (Treg) cells that suppress the effector T-cell-mediated inflammatory response [82].

5. Regulatory Gene Polymorphisms

Parasites exert a selection pressure on their hosts and are accountable for driving diversity within gene families and immune gene polymorphisms in a host population. The pathogen driven selection on immune genes can potentially alter the primed sequence and can direct to substantial changes in gene expression [1]. A number of loci were known to be associated to Treg activity. Genes such as *IL-2*, *IL-4*, *IL-10*, *IL-13*, *STAT-4*, *STAT-6*, *GITR*, *TLRs*, and *Foxp3* are established as key players in regulating Tregs [1]. The investigation of human polymorphisms in loci associated with Treg activity may underlie both susceptibility to infection and level of Treg expression. Many of these polymorphisms evolved and are maintained in a human population exposed to infectious diseases. Genotype associations may predict likely susceptibility and allow identification of subjects at the risk of developing the disease and may be subjected to therapeutic treatment.

Investigation of human polymorphisms in immune relevant genes has been used to determine the level of Treg expression and thereby the extent of susceptibility to parasitic infection [10]. The single-nucleotide polymorphisms (SNPs) in the promoter region of the genes such as *STAT6*, *Foxp3*, and *TNFRSF18* were well characterized for their functional role [4, 10, 83]. One gene of interest that plays a key role in the function of Tregs is the *IL-10* gene locus. In populations exposed to *Leishmania braziliensis* in Bahia, Brazil, genetic analysis of the *IL-10*-819C/T SNP polymorphism, located in the *IL-10* promoter, showed that the C allele increased the risk of lesions. The *IL-10*-819 C/C genotype was associated with higher levels of *IL-10* than C/T and T/T genotypes demonstrating a vital role for *IL-10* in skin lesions in humans infected with *L. braziliensis* [84]. Also, *IL-10* promoter polymorphism was recently shown to influence nonspecific total IgE levels, but not schistosomiasis-specific immunity [85]. In chagas disease low *IL-10* expression was associated with cardiac function and it was demonstrated that the polymorphic allele, which correlates with lower expression of *IL-10*, was associated with the development of chagas disease cardiomyopathy. *IL-10* gene polymorphism and *IL-10* expression are important in determining susceptibility to chagasic cardiomyopathy [86]. Also, in malaria infection it was shown that common *IL-10* promoter haplotypes condition susceptibility to severe malaria anemia and functional changes in circulating *IL-10*, TNF- α , and *IL-12* levels in children with falciparum malaria [87]. In a study among subjects infected with urinary schistosomiasis in Mali, an association was found between *STAT6* (rs324013) gene polymorphism and infection level in subjects under 20 years while the same study did not observe any association with *IL-4* and *IL4R* polymorphism [88]. *IL-13* promoter polymorphism has also been associated with urinary schistosomiasis [89].

6. Conclusion

In summary, the field of infectious disease immunology is at an exciting intersection with new concepts in regulation

of immune responsiveness. Despite extensive studies, there is still much that remains unclear about the mechanism and activities of Treg. A more comprehensive understanding of the mechanisms and gene-expression pathways that underlie the Treg activities will be essential if new therapeutic strategies are to be developed. The ability of the Treg cells to control many facets of the immune response makes them an interesting model to study possible immune-modulatory intervention.

Acknowledgments

The authors apologize to those researchers whose work has not been cited in this paper owing to space restrictions. The authors thank Dr. Benjamin Mordmüller for critical reading of this paper. They are indebted to Professor Dr. Jürgen FJ Kun (of blessed memory) for all his scientific support in all means. This project was supported by EU commission-TRANCHI (INCO-CT-2006-032436). TP. Velavan was supported by fortune grant (1916-1-0) Universitätsklinikum Tübingen and O. Ojuronbe by Alexander von Humboldt grant.





References

- [1] R. M. Maizels, "Parasite immunomodulation and polymorphisms of the immune system," *Journal of Biology*, vol. 8, no. 7, article 62, 2009.
- [2] P. Schmid-Hempel, "Parasite immune evasion: a momentous molecular war," *Trends in Ecology and Evolution*, vol. 23, no. 6, pp. 318–326, 2008.
- [3] Y. Belkaid, R. B. Blank, and I. Suffia, "Natural regulatory T cells and parasites: a common quest for host homeostasis," *Immunological Reviews*, vol. 212, pp. 287–300, 2006.
- [4] T. P. Velavan, S. Bechlars, J. Tomiuk, P. G. Kremsner, and J. F.J. Kun, "Molecular characterization of regulatory polymorphisms in the promoter region of the *STAT6* gene in a gabonese population," *Memorias do Instituto Oswaldo Cruz*, vol. 106, no. 1, pp. 65–69, 2011.
- [5] S. Sakaguchi, "Regulatory T cells: key controllers of immunologic self-tolerance," *Cell*, vol. 101, no. 5, pp. 455–458, 2000.
- [6] S. Sakaguchi, "Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance and negative control of immune responses," *Annual Review of Immunology*, vol. 22, pp. 531–562, 2004.
- [7] S. Sakaguchi, R. Setoguchi, H. Yagi, and T. Nomura, "Naturally arising Foxp3-expressing CD25(+)CD4(+) regulatory T cells in self-tolerance and autoimmune disease," *Current Concepts in Autoimmunity and Chronic Inflammation*, vol. 305, pp. 51–66, 2006.
- [8] M. Miyara and S. Sakaguchi, "Natural regulatory T cells: mechanisms of suppression," *Trends in Molecular Medicine*, vol. 13, no. 3, pp. 108–116, 2007.
- [9] Y. Belkaid, "Regulatory T cells and infection: a dangerous necessity," *Nature Reviews Immunology*, vol. 7, no. 11, pp. 875–888, 2007.
- [10] S. A. Hanel, V. Tp, P. G. Kremsner, and J. F.J. Kun, "Novel and functional regulatory SNPs in the promoter region of *FOXP3* gene in a Gabonese population," *Immunogenetics*, vol. 63, no. 7, pp. 409–415, 2011.

- [11] J. C. Lee, E. Hayman, H. J. Pegram et al., "In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy," *Cancer Research*, vol. 71, no. 8, pp. 2871–2881, 2011.
- [12] J. E. Mold, J. Michaëlsson, T. D. Burt et al., "Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero," *Science*, vol. 322, no. 5907, pp. 1562–1565, 2008.
- [13] H. von Boehmer, "Mechanisms of suppression by suppressor T cells," *Nature Immunology*, vol. 6, no. 4, pp. 338–344, 2005.
- [14] D. A. Horwitz, S. G. Zheng, and J. D. Gray, "Natural and TGF- β -induced Foxp3⁺CD4⁺CD25⁺ regulatory T cells are not mirror images of each other," *Trends in Immunology*, vol. 29, no. 9, pp. 429–435, 2008.
- [15] R. Bacchetta, E. Gambineri, and M. G. Roncarolo, "Role of regulatory T cells and FOXP3 in human diseases," *Journal of Allergy and Clinical Immunology*, vol. 120, no. 2, pp. 227–235, 2007.
- [16] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, "Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells," *Nature Immunology*, vol. 4, no. 4, pp. 330–336, 2003.
- [17] R. Haque, F. Lei, X. Xiong, and J. Song, "The regulation of FoxP3-expressing regulatory T cells," *Endocrine, Metabolic & Immune Disorders—Drug Targets*. In press.
- [18] Y. Belkaid and K. Tarbell, "Regulatory T cells in the control of host-microorganism interactions," *Annual Review of Immunology*, vol. 27, pp. 551–589, 2009.
- [19] N. Cools, P. Ponsaerts, V. F. I. Van Tendeloo, and Z. N. Berneman, "Regulatory T cells and human disease," *Clinical and Developmental Immunology*, vol. 2007, Article ID 89195, 2007.
- [20] S. Paust, L. Lu, N. McCarty, and H. Cantor, "Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 28, pp. 10398–10403, 2004.
- [21] S. Sakaguchi, N. Sakaguchi, J. Shimizu et al., "Immunologic tolerance maintained by CD25⁺ CD4⁺ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance," *Immunological Reviews*, vol. 182, pp. 18–32, 2001.
- [22] K. J. Maloy, L. Salaun, R. Cahill, G. Dougan, N. J. Saunders, and F. Powrie, "CD4⁺CD25⁺ TR cells suppress innate immune pathology through cytokine-dependent mechanisms," *Journal of Experimental Medicine*, vol. 197, no. 1, pp. 111–119, 2003.
- [23] A. L. Mellor and D. H. Munn, "IDO expression by dendritic cells: tolerance and tryptophan catabolism," *Nature Reviews Immunology*, vol. 4, no. 10, pp. 762–774, 2004.
- [24] D. H. Munn, M. D. Sharma, J. R. Lee et al., "Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase," *Science*, vol. 297, no. 5588, pp. 1867–1870, 2002.
- [25] W. J. Grossman, J. W. Verbsky, B. L. Tollefsen, C. Kemper, J. P. Atkinson, and T. J. Ley, "Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells," *Blood*, vol. 104, no. 9, pp. 2840–2848, 2004.
- [26] W. J. Grossman, J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson, and T. J. Ley, "Human T regulatory cells can use the perforin pathway to cause autologous target cell death," *Immunity*, vol. 21, no. 4, pp. 589–601, 2004.
- [27] A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis, "Mechanisms of immune suppression by interleukin-10 and transforming growth factor- β : the role of T regulatory cells," *Immunology*, vol. 117, no. 4, pp. 433–442, 2006.
- [28] M. K. Levings, R. Bacchetta, U. Schulz, and M. G. Roncarolo, "The role of IL-10 and TGF- β in the differentiation and effector function of T regulatory cells," *International archives of allergy and immunology*, vol. 129, no. 4, pp. 263–276, 2002.
- [29] M. L. Chen, M. J. Pittet, L. Gorelik et al., "Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF- β signals in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 2, pp. 419–424, 2005.
- [30] K. W. Moore, R. D. Malefyt, R. L. Coffman, and A. O'Garra, "Interleukin-10 and the interleukin-10 receptor," *Annual Review of Immunology*, vol. 19, pp. 683–765, 2001.
- [31] H. Strobl and W. Knapp, "TGF- β 1 regulation of dendritic cells," *Microbes and Infection*, vol. 1, no. 15, pp. 1283–1290, 1999.
- [32] J. R. Grainger, K. A. Smith, J. P. Hewitson et al., "Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF- β pathway," *Journal of Experimental Medicine*, vol. 207, no. 11, pp. 2331–2341, 2010.
- [33] M. Montes, C. Sanchez, K. Verdonck et al., "Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen," *PLoS Neglected Tropical Diseases*, vol. 3, no. 6, article e456, 2009.
- [34] R. M. Maizels and M. Yazdanbakhsh, "Immune regulation by helminth parasites: cellular and molecular mechanisms," *Nature Reviews Immunology*, vol. 3, no. 9, pp. 733–744, 2003.
- [35] K. Brustoski, U. Möller, M. Kramer et al., "Reduced cord blood immune effector-cell responsiveness mediated by CD4⁺ cells induced in utero as a consequence of placental Plasmodium falciparum infection," *Journal of Infectious Diseases*, vol. 193, no. 1, pp. 146–154, 2006.
- [36] A. M. Vigário, O. Gorgette, H. C. Dujardin et al., "Regulatory CD4⁺CD25⁺ Foxp3⁺ T cells expand during experimental Plasmodium infection but do not prevent cerebral malaria," *International Journal for Parasitology*, vol. 37, no. 8-9, pp. 963–973, 2007.
- [37] F. H. Amante, A. C. Stanley, L. M. Randall et al., "A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria," *American Journal of Pathology*, vol. 171, no. 2, pp. 548–559, 2007.
- [38] C. Q. Nie, N. J. Bernard, L. Schofield, and D. S. Hansen, "CD4⁺CD25⁺ regulatory T cells suppress CD4⁺ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis," *Infection and Immunity*, vol. 75, no. 5, pp. 2275–2282, 2007.
- [39] G. Minigo, T. Woodberry, K. A. Piera et al., "Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria," *PLoS Pathogens*, vol. 5, no. 4, Article ID e1000402, 2009.
- [40] S. M. Todryk, P. Bejon, T. Mwangi et al., "Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4⁺CD25^{high} T cells with susceptibility in Kenyans," *PLoS ONE*, vol. 3, no. 4, Article ID e2027, 2008.
- [41] M. Walther, J. E. Tongren, L. Andrews et al., "Upregulation of TGF- β , FOXP3, and CD4⁺CD25⁺ regulatory T cells correlates with more rapid parasite growth in human malaria infection," *Immunity*, vol. 23, no. 3, pp. 287–296, 2005.
- [42] L. L. Bueno, C. G. Morais, F. F. Araújo et al., "Plasmodium vivax: induction of CD4⁺CD25⁺FoxP3⁺ regulatory T cells during infection are directly associated with level of circulating parasites," *PLoS ONE*, vol. 5, no. 3, Article ID e9623, 2010.

- [43] Y. Wu, Q. H. Wang, L. Zheng et al., "Plasmodium yoelii: distinct CD4⁺CD25⁺ regulatory T cell responses during the early stages of infection in susceptible and resistant mice," *Experimental Parasitology*, vol. 115, no. 3, pp. 301–304, 2007.
- [44] J. Satoguina, M. Mempel, J. Larbi et al., "Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis)," *Microbes and Infection*, vol. 4, no. 13, pp. 1291–1300, 2002.
- [45] W. H. Hoffmann, A. W. Pfaff, H. Schulz-Key, and P. T. Soboslay, "Determinants for resistance and susceptibility to microfilaraemia in *Litomosoides sigmodontis* filariasis," *Parasitology*, vol. 122, no. 6, pp. 641–649, 2001.
- [46] P. T. Soboslay, C. M. Dreweck, H. R. Taylor, B. Brotman, P. Wenk, and B. M. Greene, "Experimental onchocerciasis in chimpanzees: cell-mediated immune responses, and production and effects of IL-1 and IL-2 with *Onchocerca volvulus* infection," *Journal of Immunology*, vol. 147, no. 1, pp. 346–353, 1991.
- [47] J. C. Marie, J. J. Letterio, M. Gavin, and A. Y. Rudensky, "TGF- β 1 maintains suppressor function and Foxp3 expression in CD4⁺CD25⁺ regulatory T cells," *Journal of Experimental Medicine*, vol. 201, no. 7, pp. 1061–1067, 2005.
- [48] M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, "Interleukin-10-secreting type 1 regulatory T cells in rodents and humans," *Immunological Reviews*, vol. 212, pp. 28–50, 2006.
- [49] M. D. Taylor, N. van der Werf, A. Harris et al., "Early recruitment of natural CD4⁺Foxp3⁺ Treg cells by infective larvae determines the outcome of filarial infection," *European Journal of Immunology*, vol. 39, no. 1, pp. 192–206, 2009.
- [50] H. J. McSorley, Y. M. Harcus, J. Murray, M. D. Taylor, and R. M. Maizels, "Expansion of Foxp3⁺ regulatory T cells in mice infected with the filarial parasite *Brugia malayi*," *Journal of Immunology*, vol. 181, no. 9, pp. 6456–6466, 2008.
- [51] C. A. M. Finney, M. D. Taylor, M. S. Wilson, and R. M. Maizels, "Expansion and activation of CD4⁺CD25⁺ regulatory T cells in *Heligmosomoides polygyrus* infection," *European Journal of Immunology*, vol. 37, no. 7, pp. 1874–1886, 2007.
- [52] M. S. Wilson, M. D. Taylor, A. Balic, C. A. M. Finney, J. R. Lamb, and R. M. Maizels, "Suppression of allergic airway inflammation by helminth-induced regulatory T cells," *Journal of Experimental Medicine*, vol. 202, no. 9, pp. 1199–1212, 2005.
- [53] D. P. Beiting, L. F. Gagliardo, M. Hesse, S. K. Bliss, D. Meskill, and J. A. Appleton, "Coordinated control of immunity to muscle stage *Trichinella spiralis* by IL-10, regulatory T cells, and TGF- β ," *Journal of Immunology*, vol. 178, no. 2, pp. 1039–1047, 2007.
- [54] F. S. Mariano, F. R. S. Gutierrez, W. R. Pavanelli et al., "The involvement of CD4⁺CD25⁺ T cells in the acute phase of *Trypanosoma cruzi* infection," *Microbes and Infection*, vol. 10, no. 7, pp. 825–833, 2008.
- [55] F. F. de Araújo, D. M. Vitelli-Avelar, A. Teixeira-Carvalho et al., "Regulatory T cells phenotype in different clinical forms of chagas' disease," *PLoS Neglected Tropical Diseases*, vol. 5, no. 5, 2011.
- [56] K. W. Schleifer and J. M. Mansfield, "Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins," *Journal of Immunology*, vol. 151, no. 10, pp. 5492–5503, 1993.
- [57] M. Williams, G. Oldenhove, W. Noel et al., "African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation," *Journal of Immunology*, vol. 179, no. 5, pp. 2748–2757, 2007.
- [58] J. G. Montoya, H. B. Huffman, and J. S. Remington, "Evaluation of the immunoglobulin G avidity test for diagnosis of toxoplasmic lymphadenopathy," *Journal of Clinical Microbiology*, vol. 42, no. 10, pp. 4627–4631, 2004.
- [59] E. Y. Denkers and R. T. Gazzinelli, "Regulation and function of T-cell-mediated immunity during *Toxoplasma gondii* infection," *Clinical Microbiology Reviews*, vol. 11, no. 4, pp. 569–588, 1998.
- [60] E. P. Tenorio, J. E. Olguín, J. Fernández, P. Vieyra, and R. Saavedra, "Reduction of Foxp3⁺ cells by depletion with the PC61 mAb induces mortality in resistant BALB/c mice infected with *Toxoplasma gondii*," *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 786078, 2010.
- [61] R. M. Maizels, D. A. P. Bundy, M. E. Selkirk, D. F. Smith, and R. M. Anderson, "Immunological modulation and evasion by helminth parasites in human populations," *Nature*, vol. 365, no. 6449, pp. 797–805, 1993.
- [62] Y. Belkaid, "Role of Foxp3-positive regulatory T cells during infection," *European Journal of Immunology*, vol. 38, no. 4, pp. 918–921, 2008.
- [63] T. A. Wynn, A. W. Cheever, M. E. Williams et al., "IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease," *Journal of Immunology*, vol. 160, no. 9, pp. 4473–4480, 1998.
- [64] M. Niikura, S. Kamiya, A. Nakane, K. Kita, and F. Kobayashi, "IL-10 plays a crucial role for the protection of experimental cerebral malaria by co-infection with non-lethal malaria parasites," *International Journal for Parasitology*, vol. 40, no. 1, pp. 101–108, 2010.
- [65] S. Specht, D. F. Ruiz, B. Dubben, S. Deininger, and A. Hoerauf, "Filaria-induced IL-10 suppresses murine cerebral malaria," *Microbes and Infection*, vol. 12, no. 8-9, pp. 635–642, 2010.
- [66] S. Mahanty, S. N. Mollis, M. Ravichandran et al., "High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hypo-responsiveness in human lymphatic filariasis," *Journal of Infectious Diseases*, vol. 173, no. 3, pp. 769–773, 1996.
- [67] M. Baumgart, F. Tompkins, J. Leng, and M. Hesse, "Naturally occurring CD4⁺Foxp3⁺ regulatory T cells are an essential, IL-10-independent part of the immunoregulatory network in *Schistosoma mansoni* egg-induced inflammation," *Journal of Immunology*, vol. 176, no. 9, pp. 5374–5387, 2006.
- [68] J. J. Taylor, M. Mohrs, and E. J. Pearce, "Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population," *Journal of Immunology*, vol. 176, no. 10, pp. 5839–5847, 2006.
- [69] K. P. Singh, H. C. Gerard, A. P. Hudson, T. R. Reddy, and D. L. Boros, "Retroviral Foxp3 gene transfer ameliorates liver granuloma pathology in *Schistosoma mansoni* infected mice," *Immunology*, vol. 114, no. 3, pp. 410–417, 2005.
- [70] K. Watanabe, P. N. M. Mwinzi, C. L. Black et al., "T regulatory cell levels decrease in people infected with *Schistosoma mansoni* on effective treatment," *American Journal of Tropical Medicine and Hygiene*, vol. 77, no. 4, pp. 676–682, 2007.

- [71] P. Zacccone, O. Burton, N. Miller, F. M. Jones, D. W. Dunne, and A. Cooke, "Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention in NOD mice," *European Journal of Immunology*, vol. 39, no. 4, pp. 1098–1107, 2009.
- [72] X. Wang, S. Zhou, Y. Chi et al., "CD4⁺CD25⁺ Treg induction by an HSP60-derived peptide SJMHE1 from Schistosoma japonicum is TLR2 dependent," *European Journal of Immunology*, vol. 39, no. 11, pp. 3052–3065, 2009.
- [73] R. M. Anthony, L. I. Rutitzky, J. F. Urban Jr., M. J. Stadecker, and W. C. Gause, "Protective immune mechanisms in helminth infection," *Nature Reviews Immunology*, vol. 7, no. 12, pp. 975–987, 2007.
- [74] R. Maurya, R. Kumar, V. K. Prajapati et al., "Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3⁺ CD4 cells in blood or spleen," *Parasite Immunology*, vol. 32, no. 7, pp. 479–483, 2010.
- [75] S. Mendez, S. K. Reckling, C. A. Piccirillo, D. Sacks, and Y. Belkaid, "Role for CD4⁺ CD25⁺ regulatory T cells in reactivation of persistent Leishmaniasis and control of concomitant immunity," *Journal of Experimental Medicine*, vol. 200, no. 2, pp. 201–210, 2004.
- [76] P. C. Melby, Y. Z. Yang, J. Cheng, and W. Zhao, "Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani," *Infection and Immunity*, vol. 66, no. 1, pp. 18–27, 1998.
- [77] L. Nicolas, S. Sidjanski, J. H. Colle, and G. Milon, "Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice," *Infection and Immunity*, vol. 68, no. 12, pp. 6561–6566, 2000.
- [78] T. Aebischer and E. Handman, "Influence of the route of vaccination on antigen presentation and T-cell mediated lymphokine response in murine cutaneous leishmaniasis," *Journal of Cellular Biochemistry*, vol. 64, 1993.
- [79] T. Aebischer, S. F. Moody, and E. Handman, "Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host," *Infection and Immunity*, vol. 61, no. 1, pp. 220–226, 1993.
- [80] Y. Belkaid, K. F. Hoffmann, S. Mendez et al., "The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure," *Journal of Experimental Medicine*, vol. 194, no. 10, pp. 1497–1506, 2001.
- [81] K. Yamakami, S. Akao, T. Tadakuma, Y. Nitta, J. I. Miyazaki, and N. Yoshizawa, "Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major," *Immunology*, vol. 105, no. 4, pp. 515–523, 2002.
- [82] S. N. de-Campos, C. Souza-Lemos, A. Teva, R. Porrozi, and G. Grimaldi, "Systemic and compartmentalised immune responses in a Leishmania braziliensis-macaque model of self-healing cutaneous leishmaniasis," *Veterinary Immunology and Immunopathology*, vol. 137, no. 1-2, pp. 149–154, 2010.
- [83] T. P. Velavan, S. Bechlars, X. Huang, P. G. Kremsner, and J. F. J. Kun, "Novel regulatory SNPs in the promoter region of the TNFRSF18 gene in a gabonese population," *Brazilian Journal of Medical and Biological Research*, vol. 44, no. 5, pp. 418–420, 2011.
- [84] A. Salhi, V. Rodrigues Jr., F. Santoro et al., "Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis," *Journal of Immunology*, vol. 180, no. 9, pp. 6139–6148, 2008.
- [85] A. V. Grant, M. I. Araujo, E. V. Ponte et al., "Polymorphisms in IL10 are associated with total Immunoglobulin E levels and Schistosoma mansoni infection intensity in a Brazilian population," *Genes and Immunity*, vol. 12, pp. 46–50, 2011.
- [86] G. C. Costa, M. O. D. C. Rocha, P. R. Moreira et al., "Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy," *Journal of Infectious Diseases*, vol. 199, no. 3, pp. 451–454, 2009.
- [87] C. Ouma, G. C. Davenport, T. Were et al., "Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production," *Human Genetics*, vol. 124, no. 5, pp. 515–524, 2008.
- [88] H. He, A. Isnard, B. Kouriba et al., "A STAT6 gene polymorphism is associated with high infection levels in urinary schistosomiasis," *Genes and Immunity*, vol. 9, no. 3, pp. 195–206, 2008.
- [89] A. Isnard, B. Kouriba, O. Doumbo, and C. Chevillard, "Association of rs7719175, located in the IL13 gene promoter, with Schistosoma haematobium infection levels and identification of a susceptibility haplotype," *Genes and Immunity*, vol. 12, pp. 31–39, 2011.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

